Innate Pharma Announces Third Quarter 2022 Business Update Conference Call and Webcast

0

[ad_1]

Marseille, France–(BUSINESS WIRE)– Regulatory news:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate“or the”Company”), announced today that the Company will hold a conference call on Monday, November 14, 2022 at 2:00 p.m. CET / 8:00 a.m. ET, to provide an update on the progress of the business during the third quarter of 2022.

The speakers during the call will be:

  • Mondher Mahjoubi, General Manager
  • Joyson Karakunnel, Executive Vice President, Chief Medical Officer
  • Yannis Morel, Executive Vice President, Product Portfolio Strategy and Business Development
  • Frédéric Lombard, Deputy Managing Director, Chief Financial Officer

Virtual event details

The live webcast will be available at the following link:

https://events.q4inc.com/attendee/306131452

Attendees can also join by phone to ask questions by registering before the event at: https://registrations.events/direct/Q4E60139. Upon registration, attendees will receive dial-in numbers, a direct event access code and a unique registration ID that they can use 10 minutes before the start of the event to access the event. ‘call. Call reminders will also be sent to registered attendees by email the day before the event.

This information is also available in the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company’s website for 90 days after the event.

About Innate Pharma:

Innate Pharma SA is a clinical-stage oncology-focused global biotechnology company dedicated to improving treatments and clinical outcomes for patients through antibody therapeutics that harness the immune system to fight cancer.

Innate Pharma’s large antibody portfolio includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate is a pioneer in understanding Natural Killer cell biology and has expanded its expertise in tumor microenvironment and tumor antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry, including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-product collaboration with AstraZeneca.

Based in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the United States.

Learn more about Innate Pharma at www.innate-pharma.com.

Information on Innate Pharma shares:




ISIN code


Stock code


LEI

FR0010331421


Euronext: IPH Nasdaq: IPHA


9695002Y8420ZB8HJE29

Disclaimer of forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe”, “potential”, “expect” and ” will” and similar expressions, is intended to identify forward-looking statements. Although the company believes that its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among others, uncertainties inherent in research and development, including relating to the safety, progress and results of its ongoing and planned clinical trials and preclinical studies, the review and regulatory approval of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For a further discussion of the risks and uncertainties that could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors section. (“Risk Factors”) of the Universal Registration Document filed with the Autorité des Marchés Financiers (“AMF”), available on the AMF’s website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the United States Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2021, and subsequent filings and reports filed with the AMF or the SEC, or otherwise made public, by the Company.

This press release and the information it contains do not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares of Innate Pharma in any country whatsoever.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20221106005016/en/

contacts

For more information :

Investors
Innate Pharma

Henry Wheeler
Such. : +33 (0)4 84 90 32 88
[email protected]

Media Relations

NewCap
Arthur Rusty
Such. : +33 (0)1 44 71 00 15
[email protected]

Source: Innate Pharma SA

Powered by Business Wire

Read this press release online at:

http://www.businesswire.com/news/home/20221106005016/en

[ad_2]
Source link

Share.

Comments are closed.